The Latest Cardiac and Vascular News
The novel non-DES, non-BMS COBRA PzF NanoCoated Coronary Stent (NCS) with just 14-days DAPT demonstrated statistically less bleeding (BARC 1-5) compared to the DES arm at 3 or 6 months DAPT post-PCI, low 0.6% ST and low 3.7% ischemic-driven TLR at 6 months. SAN ANTONIO, Oct. 17, 2020 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), a global medical device company […]
First-of-its-kind study evaluates ultra-short DAPT in PCI patients at high bleeding risk compared to drug-eluting stents SAN ANTONIO, June 1, 2020 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced that it has successfully completed enrollment of the COBRA REDUCE randomized control trial […]
CeloNova BioSciences’ COBRA PzF NCS is world’s first and only non drug-eluting, nanocoated coronary stent; specifically designed to treat PCI patients at high risk for bleeding complications CASTLE PINES, Colo., Jan. 8, 2020 /PRNewswire/ — Today Proximo Medical, LLC, a fractional commercial organization for start-up medical device technologies and established medical device companies looking to expand adoption in […]
SAN ANTONIO, Texas, Aug. 6, 2019 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), a global medical device company and manufacturer of the proprietary Polyzene™-F nanocoating technology, currently used to surface coat its novel COBRA PzF NanoCoated Coronary Stent (NCS), today announced appointment of seasoned medical device executive Carl J. St. Bernard as President and Chief Executive Officer to support the company’s expected […]
SAN ANTONIO, May 23, 2018 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced 1-year clinical trial results from the eCOBRA post-market study of the company’s COBRA PzF™ NanoCoated Coronary Stent (NCS) System. The clinical trial results demonstrated 4.3% target lesion […]
